Clinical research

How can diseases be treated in a better way? Findings from clinical research may answer this question.

It is extremely important to us to generate evidence for the effect of ion beam therapy or individual therapy concepts. To this end, MedAustron is running two different types of studies:

Registry study – suitable for all patients
Clinical studies – disease-specific

We ask every patient to participate in the registry study. Participation does not affect the duration, intensity or other details of treatment, but allows us to collect data that will benefit future patients.

If you are already participating in an external study, you can continue to do so during your ion beam therapy. Please inform us in this case.

Aim of studies:

Improvement of the therapy

In order to contribute to improve the knowledge about diseases and the development of new treatments,

patients are treated within the framework of clinical studies. Clinical research is the prerequisite for ensuring and further developing high-quality medical care. MedAustron plays an important role in disease- and patient-related research. Patient care does not only include diseases requiring complex treatment, but also rare or complex diseases, using the latest research.

Implementation of study measures within the framework of register study.
1 – 2
Implementation of study measures within the framework of register study.
Neurocognitive testing in the context of a registry study.
2 – 2
Neurocognitive testing in the context of a registry study.

Registry study

The aim of the registry study is to record all patients who are treated by ion beam therapy at MedAustron in order to document the clinical results (therapy response) and side effects of the therapy (toxicity).

In the course of the registry study, data on routine therapy and disease progression will be collected prospectively and in a standardized manner, as well as acute and late side effects. The resulting data analyses should ensure continuously effective and safe treatment at MedAustron. The registry study will ensure that data of the vast majority of patients (target > 90%) will be collected prospectively in order to document the efficacy and side effects of particle therapy at MedAustron. Secondary objectives are the assessment of quality of life before treatment and its changes during therapy and in the long-term course. In addition, socio-demographic data of patients will be collected in order to investigate the influence of therapy on work ability, employment, social convalescence and rehabilitation.

Clinical studies

What is a clinical study?

A clinical study is a systematic collection of patient data that examines the effectiveness and safety of a new medical treatment. A prerequisite is the existence of a clinical trial protocol, also known as study protocol. In addition to the duration of the study, this protocol specifies the criteria for the selection of study participants, which examinations (e.g. blood tests) and procedures (e.g. imaging procedures such as magnetic resonance tomography or computer tomography) are to be carried out, which form of therapy (proton therapy or carbon ion therapy) is to be administered in which dosage, and what kind of medical care will be required after completion of the study. It also describes the outcomes to be measured (endpoints) and the information to be collected. The typical endpoints are the frequencies of side effects probably related to the treatment and thus give evidence about safety, and disease control data, which reveal the effectiveness of the treatment. In the course of a study, more and more information is gained about the treatment method, the risks, how well treatment may or may not work, and how the treatment affects various aspects of life quality. The studies are conducted in accordance with the principles of good clinical practice as prescribed by the authorities in terms of protecting the study participants.

Current clinical studies at MedAustron

  • LAPC
  • PARC
  • PRLI
1 — 6


Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial) (LAPC)

This is a prospective study of high-dose hypofractionated radiotherapy for locally advanced non-metastatic pancreatic cancer

2 — 6


Preoperative, Proton Radiotherapy Combined with Chemotherapy for Borderline Resectable Pancreatic Cancer (PARC)

This is an open-label feasibility study of preoperative chemotherapy and concomitant chemo-proton therapy followed by surgery (when possible) in patients with borderline resectable pancreatic cancer.

3 — 6


Particle-based Partial Tumour Irradiation of Unresectable Bulky Tumours (PARTICLE-PATHY)

This study uses a novel, recently developed unconventional radiotherapy technique consisting of three high-dose fractions directed at specific segments of inoperable bulky tumours.

4 — 6


Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer (PRLI)

This prospective study evaluates the efficacy and safety of hypofractionated proton therapy in the treatment of medium- and low-risk prostate cancer.

5 — 6


Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease (SACRO)

This study compares surgery versus definitive radiotherapy for primary localized sacral chordoma

6 — 6


An International Clinical Program for the Diagnosis and Treatment of Children with Ependymoma (SIOP-EP-II)

Interdisciplinary oncological research

With the two divisions of radiation oncology and medical physics located at MedAustron, the center is also a teaching and research site of the Karl Landsteiner University of Health Sciences in Krems. The overall aim of the oncological research activities at KL is to use the findings from basic, translational and clinical research directly for the benefit of patients and to advance new individualized treatment procedures in systemic cancer therapy and ultra-precise radiotherapy.

Read more about it here.
Contact us

Do you have any questions about ion beam therapy or MedAustron?

Do you have any questions about the therapy or procedure? Whatever you want to know, do not hesitate to contact us. We will get back to you within two business days.

Contact Therapy request
Do you have any questions about ion beam therapy or MedAustron?
Here you will find answers

Frequently asked questions

About ion beam therapy

What is ion beam or particle therapy?

Ion beam therapy is a form of radiation therapy used to treat cancer. Protons or carbon ions are used – both are charged, massive particles.

How are the particles generated?

Protons are obtained from hydrogen gas H2, carbon ions from carbon dioxide CO2. The physical properties of protons and carbon ions are similar, but carbon ions have a much higher, so-called “biological effectiveness”.

Is ion beam therapy suitable for every type of cancer?

Compared to conventional radiotherapy with photons, particle therapy is able to reduce the radiation exposure of the adjacent healthy tissue and almost completely spare the tissue behind the tumour. Therefore, particle therapy is an ideal treatment for localized tumours in the vicinity of radiosensitive organs. Since strongly growing tissue reacts more sensitively to radiation, proton therapy is particularly suitable for cancer in children and adolescents.